Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab · Moderate to Severe HS Within the Italian Population Trial sites expanded: 16 → 22 locations
- Minor: NIS Evaluating Various Injectable and Oral Treatments · Relapsing Multiple Sclerosis Trial sites expanded: 141 → 146 locations
- Minor: Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia Trial sites expanded: 42 → 49 locations
- Minor: Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery · Early-stage, Operable, Non-small Cell Lung Cancer Trial sites expanded: 42 → 45 locations
- Minor: Biomarker Targeted Stimulation for Epileptiform Events Trial sites expanded: 0 → 4 locations
- Minor: VitaSmart HOPE System: Bridge to HOPE Registry Trial sites expanded: 1 → 9 locations
- Minor: Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit Enrollment increased: 954 → 1054 participants
- Minor: Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients Enrollment increased: 300 → 400 participants
- Minor: Canadian Critical Care Comparative Effectiveness Platform Trial sites expanded: 11 → 14 locations
- Minor: Inclisiran Versus Placebo · Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention Trial sites expanded: 149 → 153 locations
- Minor: Monotherapy With P2Y12 Inhibitors · Atrial fIbrillation Undergoing Drug-eluting Stent Implantation Trial sites expanded: 15 → 18 locations
- Minor: European Disease Registry on Retinopathy of Prematurity (ROP) Trial sites expanded: 59 → 79 locations
- Minor: Cardiogenic Shock Working Group Registry Trial sites expanded: 16 → 22 locations
- Minor: Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets · Overweight or Obesity Interventions modified
- Minor: Effects and Safety of RO7568282 in Early Parkinson's Disease Start date changed from estimate of Nov 10, 2026 to Nov 11, 2026
- Minor: Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe Trial sites expanded: 44 → 48 locations
- Minor: PF-08098488 · Advanced Solid Tumors Start date changed from estimate of Oct 29, 2026 to Nov 5, 2026
- Minor: Novel Ocular Lubricating Eye Drop Study completion moved earlier from May 2027 to Feb 2027
- Minor: Anti-cancer Drug Darolutamide · Testosterone-Driven Salivary Gland Cancers Study completion pushed from Nov 30, 2026 to Nov 12, 2027
- Minor: Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy Study completion pushed from Nov 30, 2026 to Nov 12, 2027
- Minor: Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders Start date changed from estimate of Nov 18, 2026 to Nov 10, 2026
- Minor: Comparative Evaluation of Alb PRF Versus Connective Tissue Graft in Reconstruction of Deficient Interdental Papilla Study completion moved earlier from Dec 20, 2028 to Dec 22, 2027
- Minor: Niraparib in Combination With Dostarlimab · Recurrent or Progressive Cervix Cancer Primary completion date changed from estimate of Dec 2026 to Aug 6, 2026
- Minor: TiUltra Implant Study Interventions modified
- Minor: Enhancing the Effect of Stellate Ganglion Block · PTSD: Bupivacaine vs Bupivacaine + Ketamine Interventions modified
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates